Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing.

Maurizio Salvadori, Klemens Budde, Martin Zeier, Hans Sollinger, Frederic Oppenheimer, Matthew Cooper

Journal: Transplantation reviews (Orlando, Fla.) 2013;26(4):233-40

PMID: 22863029

Full Text on Elsevier Science View on PubMed

Abstract

Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization.

Address: Division of Transplantation, University of Maryland School of Medicine, Baltimore, MD, USA. [email protected]

DOI: 10.1016/j.trre.2012.02.001

Link outs

Free resources

Medical:

https://medlineplus.gov/kidneytransplantation.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Graft Rejection, Humans, Immunosuppressive Agents, Kidney Transplantation, Mycophenolic Acid, Tablets, Enteric-Coated